Managing Director, Rick Ferdinands, reveals a New Pharmaceutical Disruption Model. This new model allows early revenue streams from ‘low risk’ listed plant based medicines, whilst drug discovery is advancing through collaborations.
Disruptive strategies such as these open the door to SMSF and sophisticated wholesale investors looking for early returns.
This presentation was delivered at the Wholesale Investor, Sydney event in June 2016.
Bioactive Laboratories welcomes its new investors, thanks existing shareholders & continues to invite SMSF investors to its register.
The Drug Development Division is powering ahead with the New Molecule Discovery project at the Eskitis Institute. The significance of this project, in creating a compound library, will add to Bioactive’s IP register of patents for commercial licensing.
The Complementary Medicine Division, creating optimised extracts, submitted its TGA New Substance application in June. This important milestone firms up customer relationships and opens the door to an FDA submission in the new financial year.
Bioactive have discovered new plant sourced molecules creating first-in-class stomach friendly anti-inflammatory and anti-microbial agents. These collectively service the global market of 7 billion people.
An investor exit is planned looking towards either a listing or a trade sale.
Bioactive Managing Director Rick Ferdinands was invited by Trade and Investment Minister, The Hon Andrew Robb AO MP to attend the Northern Australia Investment Forum in Darwin from 8 to 10 November 2015.
The forum, a high-level event, brought together senior executives from leading international and Australian companies keen to pursue investment opportunities from a select group of Australian Tropical Medicine Research Projects. The company’s Infectious Diseases Platform was showcased to an array of international entities from pharmaceutical companies, philanthropic trusts and non-profit foundations.
“Meeting senior executive decision makers from around the globe, in one place, over three days, was a unique opportunity for Bioactive. My thanks goes to Paul Field and his team from the Australian Trade Commission for organising such a productive event.”, Rick Ferdinands.
Bioactive is now working with a number of these international interests.
Bioactive has brought forward its drug development pipeline by two years after significant infectious disease discoveries were confirmed by Professor Alan Cowman, Head of Infection and Immunity at the Walter and Eliza Hall Institute of Medical Research.
Bioactive Managing Director Rick Ferdinands, “The magnitude of these discoveries has not been seen since the early 1970’s for a major global infectious disease.”
Inside 8 weeks Bioactive & the Walter and Eliza Hall institute forged a collaboration and formed a new pharmaceutical company.
The new company’s aim is two fold, to conduct additional research into the unique active compounds using structure-based drug design & to continue to develop Bioactive’s patentable Optimised Extract towards a shorter term commercial outcome.
Bioactive are now finalising patents and relationships to take advantage of this extraordinary opportunity.
“With the right global partner we could see a commercial product launch of our optimised extract within 24 months post raising.” says Mr Ferdinands.
Three consecutive years of successful Certified Organic audits have solidified the Bioactive environmental credentials by approving Certified Organic status for the US & Australian markets. The US is currently the largest regulated global organic market for traditional medicine ingredients.
The US Department of Agriculture (USDA), after the third detailed on-site audit, granted Bioactive entry into the National Organic Program (NOP) and use of the coveted USDA Certified Organic seal.
The preparation and on-site audit of the Bioactive Plant Farms in the tropical North of Western Australia, was finalised in August 2013, July 2014, and again in Sept 2015. The process initially took over 2 years in the planning, but has now become an annual event.
The USDA standards require the integration of cultural, biological and mechanical practices that foster cycling of resources, promote ecological balance and conserve biodiversity. This means that organic operations must maintain or enhance soil and water quality while also conserving wetlands, woodlands and wildlife.
Consumers globally choose to purchase organic products with the expectation that they are grown, processed and handled according to the USDA organic regulations.
This achievement adds another level of partner confidence in the Bioactive quality systems, flowing on to consumer peace of mind.
Bioactive Solutions, the Research and Development arm of the Bioactive Group are excited to announce the filing of their inaugural patent.
Managing Director Rick Ferdinands, “This patent, with research still in the discovery phase, represents a significant milestone in the short history of Bioactive.
The significance is in the non-synthetic plant based origins of the ‘herbal composition of an enriched extract’. As a proprietary formula, the patent abstract concentrates on ‘the treatment or prevention of inflammation’.
This early research indicates strong laboratory based results in four key areas: anti-inflammatory, anti-microbial, anti-oxidant and anti-cancer.
The flagship formula, Khapre®, based on this early discovery, is expected to be applied to many complementary medicine applications as an early commercial strategy to help fund the company’s drug development ambitions.
Bioactive Solutions would like to take this opportunity to congratulate the Australian Federal Government body AusIndustry on its promotion of research and development in the Agri-food & Biotechnology industries. It assists business in creating positive awareness around our industries through the R&D Tax Incentive program.
From a Bioactive point of view, this awareness and promotion assists in providing existing and potential investors with comfort and information that can positively assist their investment decisions. In addition it provides awareness to customers and business partners that the Bioactive business is forward thinking in its product pipeline planning and development.
Bioactive in cooperation with rural landowners and the South West Catchments Council (SWCC) have co-funded a grant to rehabilitate approximately 24 hectares of riparian remnant vegetation along the Blackwood River. The Blackwood River is in the South West corner of Australia in the state of Western Australia.
This initiative is part of the Bioactive Environmental Stewardship (BESt) program. The BESt program is a community focussed environmental program that supports local environmental efforts.
Bioactive Managing Director, Rick Ferdinands: “One of our prime motivators is to continue to work with community in enabling environmental stewardship. Community group the South West Catchments Council has worked tirelessly over many months with land owners to secure funding from the Australian Government’s Caring for our Country funding initiative.
With a local land owner, Bioactive will be providing a proportion of matching funding for this project. The prime objective of this initiative is to again create a vital corridor to link native animal movement in the region whilst re-populating native flora to benefit the general health of the Blackwood River.
The practical outcome of this initiative, however, is the creation of new fresh water watering points for cattle as they now have restricted access to river water. As a degraded river system with reducing annual rainfall the river water has been gradually increasing in salinity. We see this as a win/win for the environment and pastoralist. It is also an effective template that we hope can be adopted along other degraded river systems.”
Bioactive announce the signing of its inaugural materials supply agreement with a major world supplier. Subject to conditions, this independent arrangement together with Bioactive Plant Farms material will give Bioactive approximately 95% of the worlds purest active ingredients supply.
Rick Ferdinands, Group Managing Director: “This agreement is fundamental to the fast pace commercial aspirations of Bioactive. It provides a clear vote of confidence in our ability to continue to make significant discoveries in health care and take them to the market place. Our drive to commercialise early discoveries will certainly accelerate.”